Senior Scientist, Cancer Therapeutics Program, Ottawa Hospital Research Institute
Professor, Depts. of Medicine and Biochemistry, Microbiology & Immunology, University of Ottawa
Program Director, Ontario Regional Biotherapeutics Program(ORBiT), Ontario Institute for Cancer Research, OICR
Director, Canadian Oncolytic Virus Consortium (COVCo), Terry Fox New Frontiers Program Project Grant
Scientific Director, BioCanRx, Biotherapeutics for Cancer Treatment, Network of Centres of Excellence (NCE)
Research Interests and Clinical Approach
Our research program is directed towards the identification and characterization of novel cancer killing therapeutic viruses that selectively infect and kill cancer cells, while leaving healthy cells and tissues unharmed. Not only do we discover and design new therapeutic viruses, but we also manufacture them for eventual clinical translation and commercialization.
Projects at BioCanRx
Development of a Virally Programmed Exosome-based Cancer Vaccine Platform
Development of a Novel, Phase 1-Ready, Viro-Immunotherapeutic
COMBINING ONCOLYTIC VACCINE THERAPY WITH ADOPTIVE CELL THERAPY TO TARGET CANCERS EXPRESSING MAGE-A3
Recent Articles
Researchers join the fight against COVID-19
Dr. John Bell Featured on Science Podcast
John Bell Wins Inaugural ESGCT Public and Patient Engagement Award
Dr. John Bell Receives Canadian Cancer Research Alliance Award
Dr. John Bell receives award for Outstanding Achievements in Cancer Research
Dr. John Bell speaks to CBC News about the FDA approval of a second CAR-T cell therapy
New buzz about immunotherapy – A Canadian perspective with Dr. John Bell
Together, we can! A message from Dr. John Bell on World Cancer Day
